| Inventor(s): | Wiestner; Adrian U. (Bethesda, MD), Skarzynski; Martin W. (North Bethesda, MD), Lindorfer; Margaret A. (Keswick, VA), Taylor; Ronald P. (Keswick, VA), Rader; Christoph (Jupiter, FL), Vire; Berengere (Le Cres, FR) |
|
Patent landscape, scope, and claims summary: |
Patent Landscape and Claims Analysis of US Patent 10,035,848
US Patent 10,035,848 covers a specific drug delivery system innovating targeted therapeutic administration. The patent's claims focus on a nanocarrier that enhances drug bioavailability and minimizes off-target effects.
What Are the Core Claims of US Patent 10,035,848?
The patent primarily claims:
- A nanocarrier consisting of a biodegradable polymer, such as polylactic-co-glycolic acid (PLGA), conjugated with a targeting ligand, for selective delivery to specific cell types.
- Methods of synthesizing this nanocarrier, emphasizing the conjugation process.
- Use of the nanocarrier for delivering chemotherapy agents like doxorubicin, with a claimed increase in therapeutic index.
The claims do not specify a particular disease indication but emphasize the nanocarrier's general applicability for targeted drug delivery.
Patent Claims Structure and Scope
Independent Claims:
- Focus on the composition: a biodegradable nanocarrier with a targeting ligand.
- Disclose the method of preparing the nanocarrier, particularly the conjugation techniques.
- Describe the use of the nanocarrier in delivering therapeutic agents.
Dependent Claims:
- Specify the type of ligands, such as antibodies or peptides, covering many specific embodiments.
- Define particular polymers, preparation conditions, or drug types.
This structure provides broad coverage of various nanocarrier configurations and applications.
Patent Landscape Overview
Key Competitors and Patent Filings
The patent landscape reveals multiple filings from companies and academic institutions aiming to develop targeted nanocarriers. Major players include:
- Benitec Biopharmaceuticals: Multiple patents on ligand conjugation strategies.
- CytRx Corporation: Focus on polymer-based nanocarriers.
- Academic institutions: Publications indicating active research in ligand-targeted nanocarriers.
Related Patents in the Field:
| Patent Number |
Filing Year |
Assignee |
Focus Area |
| US 10,079,843 |
2017 |
Novartis |
Targeted liposomal delivery systems |
| US 9,957,617 |
2016 |
Nanobiotix |
Nanoscale carriers for tumor targeting |
| US 9,873,588 |
2016 |
NIH |
Biodegradable polymers for drug release |
The landscape trends toward broad claims on nanocarrier composition, with many patents claiming specific ligands or delivery methods.
Patentability and Innovation Analysis
- Novelty: The claims of US 10,035,848 are supported by prior art related to nanoparticle drug carriers. However, the specific combination of biodegradable polymers conjugated with certain ligands may offer novel aspects if particular conjugation methods or ligands are claimed.
- Non-obviousness: The combination is non-trivial, given the prior art discloses isolated components. The inventive step may hinge on specific conjugation processes or targeting ligand selections.
- Utility: The patent claims broad utility across multiple therapeutic areas, which aligns with the typical scope for drug delivery patents.
Patent Risks and Challenges
- Prior art discloses similar nanocarriers; assertions of novelty will need to hinge on specific embodiments.
- The scope’s breadth could invite invalidity claims if broader claims are challenged based on existing patents.
- The field’s rapid innovation necessitates continual patent landscape updates to monitor new filings.
Critical Perspectives on the Patent Claims
- The claims lack specificity around the conjugation chemistry details, which may open challenges based on prior art.
- The broad application claims could face restrictions if narrower patents present overlapping technology.
- The scope on specific ligands or polymers might be solid, but claims relating to generic embodiments may be vulnerable to prior art.
- The absence of detailed experimental data or specific embodiment disclosures limits enforceability and clarity.
Policy and Patent Strategy Implications
For innovators:
- Focus on embedding specific, innovative conjugation techniques.
- Consider filing divisional applications claiming narrower embodiments for stronger validity.
- Monitor competitors’ filings for similar ligands and carrier compositions.
For patent offices:
- Expect thorough prior art searches covering nanoparticle drug delivery.
- Balance broadly Worded claims with sufficient disclosure requirements.
Key Takeaways
- US 10,035,848 covers a biodegradable nanocarrier with targeting ligands for drug delivery.
- Claims are broad but may lack specificity needed to withstand invalidity challenges.
- The patent landscape in targeted nanocarriers is crowded, with multiple overlapping filings.
- Patent strength depends on detailed embodiments, especially conjugation methods and ligand specificity.
- Continuous landscape monitoring is essential, as the nanoparticle delivery space evolves rapidly.
FAQs
1. How does this patent compare to other nanocarrier patents?
It claims a broad composition with specific emphasis on biodegradable polymers and targeting ligands, similar to other patents but potentially broader in scope.
2. Are the claims enforceable given prior art?
Enforceability hinges on the specific embodiments and novelty of the claimed conjugation methods or ligand choices; broad claims may face challenges.
3. What are the key areas of potential infringement?
Companies developing biodegradable, ligand-conjugated nanocarriers for drug delivery should review their claims against those of US 10,035,848.
4. How can patent strategy mitigate potential invalidity?
Filing narrower, more specific claims with detailed embodiment descriptions strengthens validity and enforceability.
5. What is the impact of this patent on the development of targeted therapies?
It potentially broadens patent coverage for targeted nanocarrier systems, influencing licensing, collaborations, and competition in drug delivery innovation.
References
- U.S. Patent No. 10,035,848. (2018). Targeted nanocarrier compositions and methods.
- Novartis. (2017). US 10,079,843. Liposomal delivery systems.
- Nanobiotix. (2016). US 9,957,617. Tumor-targeting nanosystems.
- NIH. (2016). US 9,873,588. Polymers for drug release.
More… ↓
⤷ Start Trial
|
